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ABSTRACT
In 2 consecutive prospective clinical trials, we evaluated the efficacy of sirolimus together with a calcineurin
inhibitor (cyclosporine or tacrolimus) and low-dose methotrexate for prevention of graft-versus-host disease
(GVHD) after unrelated hematopoietic cell transplantation (HCT). Nine patients received sirolimus with cyclo-
sporine, and 17 received sirolimus with tacrolimus. The incidence of grade II-IV GVHD was 77%, with the
median onset at day 7 after HCT. Because of toxicity, administration of sirolimus was discontinued earlier
than planned in 11 patients, but after the onset of GVHD. Three patients developed renal failure requiring
hemodialysis. Accrual in both studies was terminated because of lack of efficacy. In these studies, the addition
of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and
provided no detectable improvement in preventing GVHD.
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Acute graft-versus-host disease (GVHD) is a major
cause of morbidity and nonrelapse mortality (NRM)
after allogeneic hematopoietic cell transplantation
(HCT) [1]. Current pharmacologic approaches to pre-
vent acute GVHD (aGVHD) generally involve the use
of a combination of immunosuppressive medications,
such as cyclosporine (CSP) or tacrolimus (TAC),
together with an antimetabolite, such as methotrexate
(MTX) [2-6]. Despite the use of these regimens, 35%-
80% of recipients develop aGVHD, often requiring
systemic immunosuppressive treatment [7-10].
Sirolimus is a macrocyclic lactone fermentation
product with antifungal and immunosuppressive ac-
tivity. The immunosuppressive effect of sirolimus is
mediated through a mechanism different from TAC
or CSP. Sirolimus blocks IL-2-induced proliferation
of T cells but does not affect signals that result inactivation-induced apoptosis. The proliferation of T
cells driven by other lymphokines, such as IL-4, IL-
12, IL-7, and IL-15, is also inhibited by sirolimus
[11]. Sirolimus inhibits lipopolysaccharide-induced
proliferation of B cells resistant to TAC and CSP
[11,12]. Although both TAC and sirolimus have the
same intracellular receptor, it is hypothesized that
the drug-immunophilin complexes interact differently
with other molecules to form functionally distinct
complexes and specific immunosuppressive effects
peculiar to each drug. Calcineurin inhibitors used in
combination with sirolimus cause an additive or syn-
ergistic suppression of immune cell function [13].
Sirolimus is effective for preventing rejection of
renal and hepatic allografts [14-17], and has been eval-
uated for treatment of aGVHD [18] and chronic
GVHD (cGVHD) [19,20]. Results of several recent
studies have suggested that sirolimus is effective for
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phase II clinical trials, we attempted to confirm the
efficacy and safety of sirolimus for preventing aGVHD
after unrelated HCT, first in combination with CSP
and MTX, and subsequently in combination with
TAC and MTX.
PATIENTS AND METHODS
The first study evaluated the immunosuppressive
regimen of CSP, sirolimus, and low-dose MTX (CSP
group). Enrollment began in December 2001, and
was terminated in May 2002. The second study evalu-
ated the combination of TAC, sirolimus, and low-dose
MTX (TAC group). Patients were enrolled between
February 2003 andMarch 2005. Results for both stud-
ies were analyzed as of March 3, 2007. The trials were
approved by the institutional review board at Fred
Hutchinson Cancer Research Center (FHCRC), and
all patients signed consent documents.
Patients
The primary inclusion criteria for patient selection
were (1) the use of a preparative conditioning regimen
containing total-body irradiation (TBI), followed by
cyclophosphamide or busulfan followed by cyclophos-
phamide; (2) an estimated creatinine clearance $70
mL/min; (3) total serumbilirubin concentrationwithin
the normal range; and (4) hepatic transaminase levels
less than twice the upper limit of normal. Patients
with diagnoses of chronic myelogenous leukemia in
the chronic phase, de novo acute leukemia in first re-
mission, and refractory anemia were excluded. HLA-
mismatching at DRB1 or DQB1 was not allowed,
although a single class 1 allele disparity was allowed.
Histocompatibility with the respective donors was
determined by high-resolution HLA-A, B, C, and
DRB1 typing and by intermediate-resolution HLA-
DQB1 typing.The protocols restricted enrollment to patients
with high-risk diagnoses, allowed a single class 1 allele
disparity, and did not restrict the type of donor graft
used, because it was felt that these criteria would not
significantly affect the protocol endpoints. For similar
reasons, the eligibility criteria allowed the use of either
of our standard myeloablative preparative condition-
ing regimens.
Treatment Plan and Supportive Care
Table 1 describes the treatment plan for each
group. Four pediatric patients in the TAC group
received 13.2 Gy TBI, and all other patients received
12.0 Gy TBI. The first study used CSP as the calci-
neurin inhibitor because CSP/MTX was our standard
GVHD prophylaxis regimen. Because we initiate
CSP therapy 1 day before the infusion of the donor
graft, sirolimus was also started on the same day. Siro-
limus blood levels were targeted at 4-14 ng/mL, which
was slightly higher than the levels targeted by the inves-
tigators at the Dana Farber Cancer Institute (DFCI).
Because of the high incidence of early-onset GVHD
observed in the CSP group, the second study
substituted TAC for CSP, with the treatment plan
and dosing schedule made identical to the regimen
used at the DFCI.When early enrollment in this study
showed a similar pattern to that seen in the CSP study,
therewas a concern that immunosuppressionwith siro-
limusmay have been inadequate. Therefore, the proto-
col was revised to increase the target level of sirolimus
to 5-12 ng/mL. Sirolimus trough levels were measured
2-3 times weekly by chromatography-tandem mass
spectrometry, and dose adjustments made to maintain
levels within the targeted range. The tablet formula-
tion of sirolimus was used throughout both studies.
In the CSP group, in the absence of toxicity, adminis-
tration of sirolimus was discontinued on day 30. In
the TAC group, the dose of sirolimus was gradually
tapered beginning on day 57, and administration wasTable 1. Treatment Plan
Cyclosporine Group Tacrolimus Group
Conditioning regimen
Total body irradiation 12 Gy (6 fractions) 12-13.2 Gy (6-8 fractions)
Cyclophosphamide 120 mg/kg (2 divided doses) 120 mg/kg (2 divided doses)
or
Busulfan 16 doses (targeted 800- 900 ng/mL) 16 doses (targeted 800-900 ng/mL)
Cyclophosphamide 120 mg/kg (2 divided doses) 120 mg/kg (2 divided doses)
GVHD prophylaxis
Sirolimus* 12 mg p.o. loading dose day 21
followed by 4 mg p.o. daily
12 mg p.o. loading dose day 23
followed by 4 mg p.o. daily
Calcineurin inhibitor Cyclosporine—1.5 mg/kg/q12 h i.v.
start day 21
Tacrolimus—0.02 mg/kg/day i.v.
start day 23
Methotrexate 5 mg/m2 i.v. days 1, 3, 6, and 11 5 mg/m2 i.v. days 1, 3, 6, and 11
Targeted levels
Sirolimus 4-14 ng/mL 3-12 ng/mL or 5-12 ng/mL
Calcineurin inhibitor Cyclosporine—150-450 ng/mL Tacrolimus— 5-10 ng/mL
*Sirolimus dosing for patients\1.5 m2 was 6 mg/m2 loading dose followed by 2 mg/m2 daily.
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continued treatment for GVHD or experienced toxic-
ity related to sirolimus.
All patients received antifungal prophylaxis with
fluconazole. Tacrolimus and CSP levels were drawn
1-3 times per week, and dose adjustments were made
to maintain therapeutic levels. In the absence of
GVHD, TAC and CSP doses were tapered starting
days 50-57 after transplantation, and administration
was discontinued on day 180. This tapering schedule
is similar to our standard practice. If patients devel-
oped GVHD, tapering of the calcineurin inhibitor
was delayed and left to the discretion of the attending
physician. Typically, tapering of CSP or TAC doses
was not begun until patients had discontinued primary
treatment for acute or chronic GVHD.
Assessment of GVHD
Acute GVHD was graded according to previously
described criteria [24]. Biopsy samples were obtained,
when appropriate, to corroborate the clinical diagnosis
of GVHD. Follow-up was censored for evaluation of
aGVHD at the time of hematologic relapse or death.
Chronic GVHD was diagnosed according to criteria
closely similar to those recommended by the NIH
Consensus Conference [25].
Toxicities
Assessment of safety focused on identifying toxic-
ities attributable to sirolimus. These included cytope-
nia, hyperlipidemia, hypercholesterolemia, hemolytic
uremic syndrome (HUS), and transaminase elevation.
The onset of engraftment was defined as the first of 3
consecutive days after HCTwhen the absolute neutro-
phil count surpassed 0.5  109/L.
RESULTS
Patient and Transplant Characteristics
All patients had high-risk hematologic malignan-
cies. Twenty-four patients had HLA-matched donors,
and 22 received granulocyte-colony stimulting factor
(G-CSF)-mobilized peripheral blood stem cells. Nine
patients were given sirolimus with CSP, and 17 were
given sirolimus with TAC (Table 2).
GVHD
Grade II-IV aGVHD was observed in 20 (77%) of
the 26 patients, 7 of 9 in the CSP group and 13 of 17 in
the TAC group (Table 3). Grade II GVHD was
observed in 14 patients (54%), grade III in 6 (23%),
and grade IV in none. GVHD was diagnosed in all 9
patients who received busulfan and cyclophospha-
mide. The median onset of GVHD occurred at day 6
in the CSP group and day 7 in the TAC group. Sixteen
of the 20 patients with GVHD had histologic confir-
mation of the diagnosis, including 13 with gastrointes-
tinal involvement. Ten patients had positive skin or
intestinal biopsies at the time of onset of GVHD or
within 1 week after the onset. All patients diagnosed
with GVHD required glucocorticoid therapy, and 4
required secondary therapy. Because of the need for
treatment of aGVHD, only 4 patients began tapering
CSP or TAC doses as planned at week 8 after HCT.
Chronic GVHD requiring systemic immunosuppres-
sive treatment developed in 6 of 7 patients in the
CSP group and in 13 of 14 patients in the TAC group
who could be evaluated. Two patients in the CSP
group and 3 patients in the TAC group could not be
Table 2. Patient and Transplant Characteristics According to Treatment
Group
CSP Group
(n 5 9)
TAC Group
(n 5 17)
Patient age, median years (range) 39 (20-65) 33 (5-52)
Disease type and stage, n
AML . CR1 or persistent disease 0 3
ALL . CR1 or persistent disease 1 7
CML—beyond chronic phase 2 3
AML from MDS 1 1
RAEB* 3 3
NHL 2 0
HLA typing, n
HLA-matched 8 16
HLA-mismatched 1 1
Stem cell source, n
G-CSF-mobilized blood cells 7 15
Marrow 2 2
Conditioning regimen, n
TBI/cyclophosphamide 5 12
Busulfan/cyclophosphamide 4 5
Donor age, median years (range) 37 (18-48) 33 (27-58)
Gender match (donor/recipient)
Male/male 3 8
Male/female 1 4
Female/male 1 5
Female/female 4 0
AML indicates acute myeloid leukemia; CR1, first complete remis-
sion; ALL, acute lymphoblastic leukemia; CML, chronic mye-
loid leukemia; MDS, myelodysplastic syndrome; RAEB,
refractory anemia with excess blasts; NHL, non-Hodgkin lym-
phoma.
*One patient had RA after treatment of RAEB2 with 5-azacytidine.
Table 3. Acute GVHD and c GVHD
Characteristic
CSP Group
(n 5 9)
TAC Group
(n 5 17)
Onset of aGVHD,median day after
HCT (range)
6 (5-23) 7 (3-100)
Acute GVHD peak grade, n
0-I 2 4
II 4 10
III-IV 3 3
Chronic GVHD requiring systemic
treatment, n
6 13
None 1 1
Not evaluated 2 3
534 T. Furlong et al.evaluated because of early death (n 5 4) or recurrent
malignancy (n 5 1).
Sirolimus, CSP, and Tacrolimus Levels
Twenty-three patients had sirolimus blood levels
drawn on the day the donor graft infusion was finished
or within 24 hours. Eighteen patients had sirolimus
levels within or above the range targeted for each
group, including 7 of 8 patients in the CSP group, in
whom sirolimus therapy was started on the day before
transplantation. Mean sirolimus blood levels through
day 30 after transplantation (or through the time of
discontinued administration, if earlier) were 11.7 ng/
mL in the CSP group and 8.8 ng/mL in the TAC
group, with only 2% and 11% of all levels below the
targeted range in each group, respectively. At the onset
of GVHD, 5 patients (26%) had sirolimus levels below
the target range. The mean CSP and TAC levels for
the same 30 day period were 324 ng/mL and 9.6 ng/
mL, respectively. Thirteen percent of all CSP levels
were below the targeted range, and no patients had
levels below the targeted range at the onset of
GVHD. Twelve percent of all TAC levels were below
the targeted range, and 2 patients had levels below the
targeted range at the onset of GVHD (Table 4).
Toxicity and Early Discontinuation of Sirolimus
Eleven of 26 patients (42%) discontinued adminis-
tration of sirolimus early because of adverse events,
including cytopenias (5), HUS or renal failure (4),
abnormal liver function tests (1), and hyperlipidemia
(1). The administration of sirolimus was discontinued
in 1 patient because of an elevated blood level (Table
4). Nine patients had sirolimus levels drawn at the
time of the adverse event, and 3 had levels above the tar-
geted range. In 2 patients, who discontinued sirolimus
therapy on days 277 and 351, the levels of sirolimus
were unknown. Four of 5 patients with cytopenias
had resolution of neutropenia or thrombocytopenia af-
ter the administration of sirolimus was discontinued.
One patient with neutropenia had recurrent malig-
nancy 21 days after the administration of sirolimus
was discontinued. Another patient with thrombocyto-
penia also had evidence of mild HUS, and this likely
contributed to the thrombocytopenia. One patient
had elevated alanine and asparate transaminase values
in the blood in the absence of GVHD and with normal
blood levels of TAC and sirolimus. After discontinuing
the administration of sirolimus, the transaminase
values returned to the normal range. One patient in
the CSP group developed rhabdomyolysis with uncer-
tain attribution to sirolimus.
Three patients in the TAC group required hemo-
dialysis. One of the patients who developed HUS had
previously experienced renal injury attributed to the
cyclophosphamide conditioning regimen. Among 5
patients who developed HUS or renal failure, 3 had
blood levels of sirolimus or the calcineurin inhibitor
above the specified target range at the onset of renal in-
sufficiency.
Five patients in the CSP Group discontinued
administration of sirolimus as planned at day 30 after
HCT, and the remaining 4 patients discontinued
administration of sirolimus on days 13, 24, 26, and 27
because of presumed toxicity. In the TAC group,
administrationof sirolimuswasdiscontinuedatamedian
of 86 days (range: 9-474) after HCT.With 1 exception,
all patients developed GVHD before sirolimus ad-
ministration was stopped. Among the 25 patients who
Table 4. Sirolimus and Calcineurin Inhibitor Levels and Toxicity
CSP Group
(n 5 9)
TAC Group
(n 5 17)
Sirolimus level (ng/mL), mean* 11.7 8.8
Sirolimus levels,* n (%)
. Target range 26 (24) 35 (18)
Within target range 80 (74) 133 (71)
\Target range 2 (2) 20 (11)
Sirolimus level at onset of
GVHD, n (%)†
Patients with level . target range 3 (43) 0 (0)
Patients with level within
target range
3 (43) 8 (67)
Patients with level\ target range 1 (14) 4 (33)
Cyclosporine level (ng/mL), mean* 324 —
Cyclosporine levels,* n (%)
. Target range 22 (22) —
Within target range 65 (65) —
\Target range 13 (13) —
Cyclosporine level at onset of
GVHD, n (%)
Patients with level . target range 1 (14) —
Patients with level within
target range
6 (86) —
Patients with level\ target range 0 (0) —
Tacrolimus level (ng/mL), mean* — 9.6
Tacrolimus levels,* n (%)
. Target range — 81 (32)
Within target range — 140 (56)
\Target range — 30 (12)
Tacrolimus level at onset of
GVHD, n (%)
Patients with level . target range — 2 (15)
Patients with level within
target range
— 9 (70)
Patients with level\ target range — 2 (15)
Reasons for discontinuation of
sirolimus, n
Cytopenia 2 3
Renal failure 1 3
Abnormal liver function tests 0 1
Elevated sirolimus level 1 0
Hyperlipidemia 0 1
*Sirolimus, TAC, and CSP levels include all measurements through
day 30 afterHCTor until administration was discontinued, if earlier.
The mean levels are for the same time period.
†One patient in the TAC Group stopped sirolimus administration
before the onset of aGVHD.
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at a median of 16 days (range: 10-28) after HCT.
Nine patients received targeted oral busulfan ther-
apy as part of their preparative conditioning regimen,
with levels targeted, in most cases, at 800-900 ng/
mL. Seven patients had mean busulfan levels within
the targeted range. Two patients had mean levels of
923 ng/mL and 952 ng/mL.
Outcome
Nineteen of 21 patients (90%) who could be evalu-
ated developed cGVHD. Twenty-one (81%) and 16
patients (62%) were alive at 6 months and 1 year after
HCT, respectively (Figure 1). Twelve (46%) remain
alive at a median of 1106 days after HCT. Three
patients had recurrent malignancy and died. Eleven
patients died from other causes: respiratory failure
(not infection) (4), cardiac arrest (2), hepatic failure
(2), GVHD (1), infection (1) andmultiorgan failure (1).
DISCUSSION
In these 2 studies, the addition of sirolimus to
a standard calcineurin inhibitor plus MTX regimen
provided no detectable improvement in preventing
GVHD after unrelated HCT. Accrual in the CSP
group was terminated when 7 of 9 patients developed
aGVHD at a median of 6 days after HCT. When 13
of 17 patients in the TAC group developed aGVHD
at a median of 7 days after HCT, the protocol was
closed to further enrollment.
The immunosuppressive regimen of sirolimus,
TAC, and MTX for patients in the TAC group of
our study was identical to that used at theDFCI, where
the incidence of aGVHD after unrelated HCT was
26% [22]. It is difficult to explain why our results differ
so greatly from theDFCI experience. Review of patient
selection criteria and treatment methods has identified
several differences between the 2 studies, but none of
these differences can be easily invoked as likely expla-
nations for the disparate results. The DFCI study
enrolled only adults, whereas we enrolled adults and
children. The DFCI patients received a conditioning
regimenof cyclophosphamide followed by fractionated
TBI, whereas patients who received a TBI-based regi-
men at our center were given TBI followed by cyclo-
phosphamide. It is unlikely that this scheduling of
therapy would explain the high incidence of aGVHD
seen in this study, because all patients who received bu-
sulfan and cyclophosphamide also developed aGVHD.
The dose of cyclophosphamide was slightly lower for
DFCI patients than for FHCRC patients, but the
TBI exposure in the DFCI study (14 Gy) was slightly
higher than in our study. The DFCI patients were
given clotrimazole and nonabsorbable antibiotics until
engraftment, whereas FHCRCpatients were given flu-
conazole and levofloxacin (adults) or ceftazidime (chil-
dren) to prevent infection during neutropenia. There
were no obvious differences in sirolimus blood levels
between the 2 studies, and the ranges used in our stud-
ies for targeting sirolimus levels were identical to or
higher than those used in the DFCI study. Nearly all
patients in our studies had levels of CSP orTACwithin
or above the targeted range at the onset of GVHD. Of
note, the dose of MTX used in these studies was lower
than the standard dose used at our center for GVHD
prophylaxis after HCT with myeloablative condition-
ing regimens. Although early blood levels of CSP or
TAC and sirolimus were within the targeted range in
most patients, it is possible that the reduced dosing of
MTX contributed to inadequate immunosuppression
early after transplantation.
Our schedule for discontinuing administration of
sirolimus, particularly in the CSPGroup, was different
from that used in the DFCI study. All patients in the
CSP Group had sirolimus therapy discontinued on or
before day 30 after transplantation. In the TACGroup
administration of sirolimus was discontinued at a me-
dian of 86 days after transplantation. The impact
of this schedule on the incidence of aGVHD is not sig-
nificant, as all patients, except 1, in both studies devel-
oped GVHD before the discontinuation of sirolimus
therapy.
It is possible that the grading of GVHD differs be-
tween centers, and the threshold severity of GVHD
required to prompt treatment may also differ. The
incidence of grades II-IV aGVHD after unrelated
HCT with myeloablative conditioning at our center
has been approximately 80%, substantially higher
than the rates reported from other centers [10]. We
have published evidence suggesting that sensitivity
for making the diagnosis of gastrointestinal GVHD
might be higher at our center than at other centers
[10]. The consistent early presentation of GVHD in
the present studies was highly atypical in our experi-
ence. The early onset of symptoms might suggest the
development of an engraftment syndrome. If so, treat-
ment with a short course of high-dose glucocorticoidsFigure 1. Relapse and overall and event-free survival for all patients.
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tested, and the patients were treated with glucocorti-
coids per our standard practice for management of
aGVHD.Of note, a high incidence of engraftment syn-
dromewas notmentioned in the report from theDFCI.
Risk factors for the development of hyperacute
GVHD following HCT have been identified by Saliba
et al. [26]. These factors include a donor/recipient (fe-
male/male) gendermismatch, the use ofHLA-matched
unrelated donor grafts, the use of a myeloablative pre-
parative conditioning regimen, and treatment with
more that 5 prior chemotherapy regimens prior to
transplantation. All of the patients in these studies re-
ceived unrelated donor grafts following amyeloablative
preparative conditioning regimen. All had high-risk
hematologic malignancies likely requiring multiple
courses of chemotherapy prior to transplantation. Six
male patients received grafts from female donors.
Although the demographic characteristics of our study
cohort includedmany of these risk factors, this group is
similar to the population of patients who receive unre-
lated HCT at our institution, yet the onset of GVHD
among the patients receiving sirolimus was distinctly
earlier than what we normally expect. In a multicenter
trial comparing CSP/MTX versus TAC/MTX for
GVHD prophylaxis following unrelated donor trans-
plantation [3], the median time of onset of GVHD
wasmuch later than thatobserved in the current studies.
In the setting of myeloablative HCT for patients
with high-risk malignancies, it is difficult to attribute
the occurrence and severity of any specific adverse
event to sirolimus alone. On the other hand, some of
the adverse events that we observed in the current study
have been previously reported in GVHD treatment
and renal transplant studies with sirolimus [15,18-20].
For example, neutropenia has been reported to occur
in 5%-19% of patients and thrombocytopenia in
9%-57% of patients. In the current studies, 4 of the 5
patients who experienced neutropenia or thrombocy-
topenia had resolution of the cytopenia following
discontinuation of sirolimus therapy. In a study evalu-
ating the use of sirolimus for treatment of cGVHD, 7of
19 patients discontinued sirolimus therapy because of
adverse events [20]. Six of these 7 patients developed
HUS or acute renal insufficiency, and the study was
closed to accrual earlier than originally planned be-
cause of a high incidence of toxicity. Even with close
monitoring of blood levels, combination regimens of
sirolimus and calcineurin inhibitors may have a very
narrow therapeutic index.
Eleven of the 14 deaths in our study were related to
causes other than relapse, with 4 deaths within the first
100 days after transplantation.With the exception of 4
patients who died with noninfectious pulmonary com-
plications, the other causes of death varied, with no
single dominant cause to explain the high rate of non-
relapse deaths. The high rate of NMR observed in thisstudy may be related to effects of intensive chemother-
apy before referral for transplantation, limited ability
to tolerate the conditioning and immunosuppressive
regimens, as well as the early onset of aGVHD.
In conclusion, we found no evidence for improved
prevention of GVHD after adding sirolimus to the
combination of methotrexate and a calcineurin inhi-
bitor after unrelated HCT. Moreover, we found an
unusually high incidence of complications that we be-
lieve were caused by administration of sirolimus. Our
results sound a note of caution in future clinical trials
testing the safety and efficacy of sirolimus for GVHD
prophylaxis after unrelated HCT.
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